KRAS mRNA Spleen‐Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer
Advanced Science · 2025-09 · 12 (34)
DOI: 10.1002/advs.202504886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 11.06.2025. Verfasst von Lijia Luo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Irinotecan, Pancreatic Neoplasms, Nanoparticle Drug Delivery System. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, U.S. Public Health Service, National Cancer Institute in the USA.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies due to its immunosuppressive tumor microenvironment. It is hypothesized that overcoming these barriers requires a dual approach: inducing immunogenic tumor cell death (ICD) and enhancing the cancer immunity cycle by exogenous neoantigen targeting on the spleen. In this study, a novel strategy is presented combining irinotecan‐loaded silicasomes with spleen‐targeting lipid nanoparticles (LNPs) carrying KRAS G12D mRNA and the toll‐like receptor 7/8 (TLR7/8) agonist 3M‐052. The goal is to establish a cancer immunity cycle by promoting endogenous tumor antigen release by the generation of KRAS‐specific cytotoxic T cells. Using an orthotopic PDAC mouse model, it is demonstrated that this dual‐platform approach significantly reduces tumor burden and extends survival compared to monotherapies. Bulk RNA sequencing and gene expression analyses further reveal synergy between the immune responses at the primary tumor site and the spleen, including maximal upregulation of apoptosis‐related genes, endoplasmic reticulum stress pathways, antigen presentation pathways, and T cell activation markers. These findings indicate that the combinatorial strategy effectively bridges innate and adaptive immunity. In conclusion, this study highlights the potential of nanocarrier‐based immunotherapy to enhance PDAC immunity by integrating ICD induction with systemic immune reprogramming, offering a promising avenue for improving treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
- California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
ORCID-Profile: Lijia Luo, Xiang Wang, Yu-Pei Liao, Andre E Nel
Förderung
- NCI NIH HHS
- U.S. Public Health Service
- National Cancer Institute in the USA
Zitieren
APA
Luo, L., Wang, X., Liao, Y. P., & Nel, A. E. (2025). KRAS mRNA Spleen‐Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer. Advanced Science, 12(34). https://doi.org/10.1002/advs.202504886
Vancouver
Luo L, Wang X, Liao YP, Nel AE. KRAS mRNA Spleen‐Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer. Advanced Science. 2025;12(34). doi:10.1002/advs.202504886
BibTeX
@article{Luo2025,
author = {Luo, Lijia and Wang, Xiang and Liao, Yu-Pei and Nel, Andre E},
title = {KRAS mRNA Spleen‐Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {34},
doi = {10.1002/advs.202504886}
}
EUVIMED